Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ARGX

Argen X SE ADR

Sep 15 • 03:57PM ET

756.49

+0.11 0.01 %

Healthcare • Biotechnology • Netherlands • NASD

Peers: REGN VRTX BIIB INCY IONS GILD NBIX RCUS FGEN XBIT

| Held by: IBB CGGO FBT BBH QQQJ DFAI AVDE ONEQ TGRT FDG

Scroll to Statements

Index	-	P/E	38.46	EPS (ttm)	19.67	Insider Own	0.40%	Shs Outstand	61.20M	Perf Week	-1.50%
Market Cap	46.30B	Forward P/E	30.46	EPS next Y	24.84	Insider Trans	0.00%	Shs Float	60.96M	Perf Month	15.95%
Enterprise Value	42.41B	PEG	1.01	EPS next Q	4.45	Inst Own	54.20%	Short Float	2.95%	Perf Quarter	30.91%
Income	1.28B	P/S	15.12	EPS this Y	20.55%	Inst Trans	10.44%	Short Ratio	4.26	Perf Half Y	25.05%
Sales	3.06B	P/B	7.59	EPS next Y	61.22%	ROA	21.42%	Short Interest	1.80M	Perf YTD	23.01%
Book/sh	99.66	P/C	11.79	EPS next 5Y	37.98%	ROE	24.75%	52W High	779.03 -2.89%	Perf Year	40.76%
Cash/sh	64.19	P/FCF	86.30	EPS past 3/5Y	- -	ROIC	20.91%	52W Low	510.05 48.32%	Perf 3Y	91.15%
Dividend Est.	-	EV/EBITDA	101.76	Sales past 3/5Y	63.91% 94.72%	Gross Margin	88.95%	Volatility	2.40% 2.06%	Perf 5Y	240.76%
Dividend TTM	-	EV/Sales	13.85	EPS Y/Y TTM	708.35%	Oper. Margin	12.89%	ATR (14)	17.14	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	5.27	Sales Y/Y TTM	89.58%	Profit Margin	41.87%	RSI (14)	74.31	Recom	1.33
Dividend Gr. 3/5Y	- -	Current Ratio	5.60	EPS Q/Q	-	SMA20	5.81%	Beta	0.47	Target Price	827.95
Payout	0.00%	Debt/Eq	0.01	Sales Q/Q	-	SMA50	16.27%	Rel Volume	0.53	Prev Close	756.38
Employees	1599	LT Debt/Eq	0.01	Earnings	Jul 31 BMO	SMA200	22.52%	Avg Volume	422.54K	Price	756.49
IPO	May 18, 2017	Option/Short	Yes / Yes	EPS/Sales Surpr.	21.09% 10.21%	Trades		Volume	221,351	Change	0.01%

Date	Action	Analyst	Rating Change	Price Target Change
Today	Resumed	Truist	Buy	$918
Sep-11-25	Downgrade	Deutsche Bank	Buy → Hold
Aug-25-25	Initiated	RBC Capital Mkts	Outperform	$850
Jul-08-25	Upgrade	Deutsche Bank	Hold → Buy
Jul-03-25	Resumed	Morgan Stanley	Overweight	$700
May-13-25	Upgrade	Robert W. Baird	Neutral → Outperform	$680
Mar-17-25	Upgrade	Bernstein	Mkt Perform → Outperform
Mar-12-25	Upgrade	Deutsche Bank	Sell → Hold
Jan-17-25	Downgrade	Deutsche Bank	Hold → Sell
Nov-12-24	Upgrade	Wolfe Research	Peer Perform → Outperform	$697
Nov-05-24	Upgrade	Scotiabank	Sector Perform → Sector Outperform	$715
Nov-01-24	Upgrade	William Blair	Mkt Perform → Outperform
Nov-01-24	Downgrade	Robert W. Baird	Outperform → Neutral	$515 → $650
Oct-10-24	Resumed	Raymond James	Strong Buy	$605
Oct-04-24	Downgrade	Deutsche Bank	Buy → Hold
Aug-06-24	Upgrade	Barclays	Equal Weight → Overweight
Jul-25-24	Upgrade	Deutsche Bank	Hold → Buy
Jul-23-24	Upgrade	Oppenheimer	Perform → Outperform	$546
Feb-15-24	Initiated	Wolfe Research	Peer Perform
Dec-20-23	Downgrade	William Blair	Outperform → Mkt Perform

Show Previous Ratings

Sep-14-25 01:16AM	Deutsche Bank Downgrades Argenx SE (ARGX) to Hold From Buy (Insider Monkey)
Sep-11-25 11:16AM	argenx SE (ARGX) Expands Autoimmune Leadership with Vyvgart Launch (Insider Monkey)
Sep-08-25 04:06PM	Why Dianthus Therapeutics, Up 47% In Four Weeks, Just Surged Again (Investor's Business Daily)
Sep-03-25 06:55PM	Analyst Report: argenx SE (Morningstar Research)
Sep-02-25 08:47AM	Air Lease Agrees To $7.4 Billion Takeout By Japan-Led Group (Investor's Business Daily)
12:20PM	Loading…
Sep-01-25 12:20PM	3 Healthcare Pathbreakers With Long-Term Tailwinds (MarketBeat)
11:40AM	KMDA or ARGX: Which Is the Better Value Stock Right Now? (Zacks)
Aug-28-25 01:00AM	argenx to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-26-25 04:36PM	Argenx Stock Hits Record High After Reporting 664% Earnings Surge; This Rating Upgraded (Investor's Business Daily)
Aug-25-25 09:36AM	Figma initiated, Okta upgraded: Wall Street's top analyst calls (The Fly)
09:22AM	Argenx Tops Buy Point On Bullish Study, 850 Price Target (Investor's Business Daily)
01:00AM	argenx Announces Positive Topline Results from ADAPT SERON Study of VYVGART in Patients with AChR-Ab Seronegative gMG (GlobeNewswire)
Aug-19-25 01:00AM	argenx to Host R&D Webinar Highlighting ARGX-119 on September 16, 2025 (GlobeNewswire)
Aug-18-25 11:38PM	Analyst Report: argenx SE (Morningstar Research)
Aug-16-25 11:42PM	argenx SE (ARGX): A Bull Case Theory (Insider Monkey)
04:24PM	Loading…
Aug-15-25 04:24PM	How Argenx's 'Blowout' Quarter Sparked A Blazing 31% Monthlong Run (Investor's Business Daily)
Aug-12-25 06:45AM	argenx and Tennis Legend Monica Seles Team Up to Raise Awareness of Myasthenia Gravis (GlobeNewswire)
Aug-07-25 07:43AM	Here's What Pulled Down Argenx (ARGX) in Q2 (Insider Monkey)
Jul-31-25 08:50PM	Analyst Report: argenx SE (Morningstar Research) +11.93%
08:09AM	Should You be Confident in Argenx SE (ARGX)? (Insider Monkey)
01:00AM	argenx Reports Half Year 2025 Financial Results and Provides Second Quarter Business Update (GlobeNewswire)
Jul-28-25 02:07AM	Argenx SE (ARGX) Gets Upgraded to Buy From Hold at Deutsche Bank (Insider Monkey)
Jul-24-25 01:00AM	argenx to Report Half Year 2025 Financial Results and Second Quarter Business Update on July 31, 2025 (GlobeNewswire)
Jul-21-25 11:40AM	EXEL vs. ARGX: Which Stock Should Value Investors Buy Now? (Zacks)
Jul-03-25 11:40AM	EXEL or ARGX: Which Is the Better Value Stock Right Now? (Zacks)
Jun-30-25 11:31AM	BofA Remains Bullish on Argenx (ARGX) With a Buy Rating and $804 PT (Insider Monkey)
01:00AM	argenx Advances Clinical Development of ARGX-119 in Congenital Myasthenic Syndromes (GlobeNewswire)
Jun-24-25 12:45PM	Argenx Secures EC Approval for Subcutaneous VYVGART in CIDP Treatment (Insider Monkey) +5.05%
Jun-20-25 01:00PM	argenx Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy (GlobeNewswire)
Jun-17-25 11:40AM	EXEL or ARGX: Which Is the Better Value Stock Right Now? (Zacks)
06:01PM	Loading…
Jun-10-25 06:01PM	argenx Presents New Efgartigimod Data at EULAR 2025 Highlighting Positive Phase 2 Proof-of-Concept Results in Myositis and Sjogren's Disease (GlobeNewswire)
Jun-06-25 04:30PM	argenx SE (ARGX): A Bull Case Theory (Insider Monkey)
04:00PM	This IBD 50 Biotech's Got 'Rhythm' And Flashes 3 Telltale Clues (Investor's Business Daily)
Jun-03-25 09:09AM	Nurix Therapeutics (NRIX) Moves 14.2% Higher: Will This Strength Last? (Zacks)
01:00AM	argenx to Present at Goldman Sachs 46th Annual Global Healthcare Conference (GlobeNewswire)
May-29-25 09:00AM	Argenx added to Best Ideas List at Wedbush (TipRanks)
May-28-25 04:01PM	argenx Announces Results of Annual General Meeting of Shareholders (GlobeNewswire)
May-23-25 11:40AM	EXEL vs. ARGX: Which Stock Is the Better Value Option? (Zacks)
May-13-25 10:16PM	argenx SE (ARGX): Among the Best Growth Stocks to Buy and Hold for the Long Term (Insider Monkey)
May-12-25 12:00PM	Argenx (ARGX) Upgraded to Buy: Here's Why (Zacks)
May-09-25 08:30PM	Analyst Report: argenx SE (Morningstar Research)
10:25AM	argenx SE (ARGX): Among the Best Cancer Stocks to Invest in for Long-Term Gain (Insider Monkey)
03:18AM	argenx SE (ARGX) Q1 2025 Earnings Call Highlights: Record Growth and Strategic Advances (GuruFocus.com)
May-08-25 08:55AM	Argenx Beats Sales Expectations But Not By Enough And Shares Tumble (Investor's Business Daily) -8.64%
01:00AM	argenx Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
May-07-25 06:00PM	Here are the major earnings before the open tomorrow (Seeking Alpha)
12:11PM	Argenx SE Q1 2025 Earnings Preview (Seeking Alpha)
11:02AM	argenx SE (ARGX): A Bull Case Theory (Insider Monkey)
04:55AM	Fidelity Select Health Care Portfolio Q1 2025 Commentary (Seeking Alpha)
May-06-25 11:40AM	AZN or ARGX: Which Is the Better Value Stock Right Now? (Zacks) -6.33%
01:00AM	argenx to Present at BofA Securities 2025 Health Care Conference (GlobeNewswire)
May-05-25 12:12PM	ANI Pharmaceuticals to Report Q1 Earnings: Is a Beat in the Cards? (Zacks)
09:54AM	Perrigo to Report Q1 Earnings: Is a Beat in Store for the Stock? (Zacks)
07:12AM	Novavax to Report First-Quarter Earnings: Is a Beat in Store? (Zacks)
May-02-25 01:23PM	BioMarin's First-Quarter Earnings & Sales Beat Estimates (Zacks)
May-01-25 03:33AM	Is argenx SE (ARGX) the Most Profitable Growth Stock to Buy Now? (Insider Monkey)
01:00AM	argenx to Report First Quarter 2025 Financial Results and Business Update on May 8, 2025 (GlobeNewswire)
Apr-30-25 10:55PM	ClearBridge International Growth Fund Q1 2025 Commentary (Seeking Alpha)
01:06PM	Argenx Stock Extends Rally In A Base As Earnings Loom (Investor's Business Daily)
09:40AM	Is Roche Holding (RHHBY) Stock Outpacing Its Medical Peers This Year? (Zacks)
Apr-29-25 11:59AM	Corcept Therapeutics to Report Q1 Earnings: What's in the Cards? (Zacks)
07:51AM	Vertex Gears Up to Report Q1 Earnings: Is a Beat in the Cards? (Zacks)
Apr-28-25 09:14AM	GSK to Report First-Quarter Earnings: Is a Beat in Store? (Zacks)
09:04AM	Zoetis Gears Up to Report Q1 Earnings: Here's What to Expect (Zacks)
01:00AM	argenx Announces Positive CHMP Opinion for VYVGART (efgartigimod alfa) Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (GlobeNewswire)
Apr-27-25 02:22PM	Baron Health Care Fund Q1 2025 Shareholder Letter (Seeking Alpha)
Apr-25-25 01:29PM	Exelixis' Q1 Earnings: Will Cabometyx Maintain Momentum? (Zacks)
11:57AM	Can Moderna Keep the Beat Streak Alive This Earnings Season? (Zacks)
11:16AM	Recursion Pharmaceuticals to Report Q1 Earnings: What's in the Cards? (Zacks)
10:14AM	CytomX Gears Up to Report Q1 Earnings: Here's What to Expect (Zacks)
09:25AM	Beam Therapeutics to Report Q1 Earnings: What's in the Cards? (Zacks)
Apr-24-25 10:15AM	Artisan International Fund Q1 2025 Commentary (Seeking Alpha)
09:55AM	Wall Street Analysts Believe Argenx (ARGX) Could Rally 25.8%: Here's is How to Trade (Zacks)
Apr-23-25 09:25AM	Amicus Therapeutics to Report Q1 Earnings: What's in the Cards? (Zacks)
07:50AM	Incyte Gears Up to Report Q1 Earnings: Here's What You Should Know (Zacks)
Apr-22-25 10:39AM	Verastem Oncology to Report Q1 Earnings: What's in the Cards? (Zacks)
Apr-21-25 07:36AM	Viking Therapeutics to Report Q1 Earnings: What's in the Cards? (Zacks)
Apr-17-25 11:40AM	JAZZ vs. ARGX: Which Stock Is the Better Value Option? (Zacks)
Apr-15-25 08:09AM	Argenx (ARGX) Moves 4.4% Higher: Will This Strength Last? (Zacks)
Apr-14-25 02:03PM	Is Argenx SE (ARGX) the Best Growth Stock to Buy According to Billionaires? (Insider Monkey)
Apr-11-25 05:41PM	FDA Approves Argenx's Vyvgart Hytrulo Prefilled Syringe For Self-Injection For At Home Use Setting (Benzinga) +6.36%
04:01PM	argenx Announces Annual General Meeting of Shareholders on May 27, 2025 (GlobeNewswire)
10:15AM	Argenx Bounds Off 200-Day Line On 'Best-Case Scenario' For Blockbuster Drug (Investor's Business Daily)
Apr-10-25 05:47PM	argenx Announces FDA Approval of VYVGART Hytrulo Prefilled Syringe for Self-Injection in Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy (GlobeNewswire)
01:26PM	argenx SE (ARGX): Among the Aggressive Stocks Picked by Hedge Funds (Insider Monkey)
Apr-09-25 06:33AM	ClearBridge International Growth EAFE Strategy Q1 2025 Commentary (Seeking Alpha)
Apr-08-25 02:17PM	Argenx's Flagship Drug Vyvgart Shows Sustained Disease Control In Rare Neuromuscular Disease Patients (Benzinga)
01:00AM	argenx Highlights VYVGART Data at AAN 2025 Setting New Standard in Sustained Efficacy and Improved Quality of Life Measures for Patients Living with gMG and CIDP (GlobeNewswire)
Apr-04-25 02:30PM	Stock Picks From Seeking Alpha's March 2025 New Analysts (Seeking Alpha) -5.92%
Apr-02-25 09:47AM	Is Argenx SE (ARGX) The Most Profitable Biotech Stock To Buy Right Now? (Insider Monkey)
Mar-31-25 11:40AM	JAZZ or ARGX: Which Is the Better Value Stock Right Now? (Zacks)
Mar-27-25 07:30AM	Franklin Biotechnology Discovery Fund Q4 2024 Commentary (SeekingAlpha)
Mar-24-25 01:56PM	Argenx: The Magic May Be Already Priced In (SeekingAlpha)
Mar-19-25 05:07PM	Immunovant: TED Data Sets Stage For Batoclimab Regulatory Filings Going Forward (SeekingAlpha)
Mar-17-25 09:35AM	Argenx (ARGX) Surges 4.1%: Is This an Indication of Further Gains? (Zacks)
Mar-11-25 08:17AM	Artisan Small Cap Fund Sold argenx SE (ARGX) as it Exceeded Small-Cap Mandate (Insider Monkey)
Mar-07-25 01:00AM	argenx Highlights FcRn Leadership with Long-term Data and Transformational Patient Outcomes at the American Academy of Neurology 2025 Annual Meeting (GlobeNewswire)
Mar-04-25 04:50PM	Biohaven Slumps, Again, As Bipolar Setback Outweighs A $4 Billion Opportunity (Investor's Business Daily)
Feb-28-25 09:24PM	Analyst Report: argenx SE (Morningstar Research)
Feb-27-25 01:00AM	argenx Reports Full Year 2024 Financial Results and Provides Fourth Quarter Business Update (GlobeNewswire)

argenx SE is a global immunology company, which engages in improving the lives of people suffering from severe autoimmune diseases. It operates through the following geographical segments: United States, Japan, EMEA, and China. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren in 2008 and is headquartered in Amsterdam, the Netherlands.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ARGX

Argen X SE ADR

Upgrade your FINVIZ experience